Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07600112
Active, not recruiting Not applicable

Endoscopic Versus Conventional Parotidectomy for Benign Parotid Tumors

NCT07600112 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Not applicable
Started
2026-05-01
Last updated
2026-05-20

Condition(s) studied

Parotidectomy

Investigational drug(s) / intervention(s)

Endoscopic Parotidectomy GroupActive Comparator Intervention Conventional Parotidectomy

Endoscopic Parotidectomy Group: Minimally invasive endoscopic-assisted parotidectomy performed through anterior chest wall approach for benign parotid tumors.

Active Comparator Intervention Conventional Parotidectomy: Conventional open parotidectomy performed through modified Blair incision for management of benign parotid tumors.

Study summary

To compare endoscopic and conventional parotidectomy in the management of benign parotid tumors regarding surgical outcomes, facial nerve preservation, operative time, postoperative complications, and cosmetic results, in order to evaluate the safety, feasibility, and potential advantages of the endoscopic minimally invasive technique.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults aged 18 years or older 2. Patients with benign parotid tumors involving the superficial lobe of the parotid gland 3. Tumors located in the inferior pole with or without limited deep lobe extension 4. Tumor size suitable for minimally invasive approach ≤4 cm 5. Patients fit for surgery under general anesthesia 6. Patients willing to provide informed consent and comply with follow-up Exclusion Criteria: 1. Recurrent parotid tumors 2. Previous parotid surgery on the affected side 3. Pre-existing facial nerve dysfunction 4. Previous neck surgery or extensive cervical/anterior chest wall scarring 5. Significant comorbidities contraindicating surgery or general anesthesia 6. Suspected or confirmed malignant parotid tumors

Primary outcome measure(s)

  • Surgical safety and feasibility — During surgery and up to 3 months postoperatively.
    Assessment of intraoperative and postoperative complications and conversion rate to open surgery.
  • Facial nerve function — 24 hours, 1 week, 1 month, and 3 months postoperatively.
    Assessment using House-Brackmann grading system.

Trial sites (1)

FacilityCityRegionStatus
Department of General Surgery, Maxillofacial and Head and Neck Unit Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07600112 on ClinicalTrials.gov ↗ ← All trials in Egypt